CER is off 35% from its recent highs on no news that wasnt already publically available. CER is now rediculously oversold and will run back to those levels upon confirming the refinancing.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%